Docosahexaenoic Acid (DHA) Inhibits Bone Morphogenetic Protein-2 (BMP-2) Elevated Osteoblast Potential of Metastatic Breast Cancer (MDA-MB-231) Cells in Mammary Microcalcification.

Abstract

Microcalcification seems to be an assurance signature for the prediction of breast cancer malignancy. However, neither systematic study for deciphering the molecular mechanism of mammary microcalcification has yet been conducted, nor a mechanistic study has been performed to find out its prevention. Thus, this study firstly aimed at determining if malignant breast tissues/metastatic breast cancer cells exhibit elevated intrinsic osteoblast-like potential responsible for driving the pathological microcalcification in breast tumors. Here, tumor sample analysis showed higher levels of various osteogenic genes (e.g., Runx2, osterix), and increased ALP activity and calcification in malignant breast tissues when compared to benign tissues, indicating the existence of elevated osteoblast-like potential in malignant breast tissues as compared to benign tissues. Similarly, cell culture study found that metastatic MDA-MB-231 cells acquired a higher osteoblast-like potential as compared to less metastatic breast cancer MCF-7 cells. It was also noticed that osteoinducer bone morphogenetic protein 2 (BMP-2) increased osteoblast-like differentiation and calcification potential in breast cancer cells. Moreover, omega-3 fatty acid docosahexaenoic acid (DHA) showed an inhibitory effect on BMP-2 induced osteoblast-like potential presumably by abrogating BMP signaling. Thus, this study for the first time unraveled that DHA may mitigate microcalcification by blocking osteoblast-like potential of breast cancer cells.

• Authors: Tanu Sharma, Ankit Sharma, Rekha Maheshwari, Geeta Pachori, Poonam Kumari, Chandi C Mandal
• Journal: Nutrition and cancer (Nutr Cancer) Vol. 72 Issue 5 Pg. 873-883 ( 2020) ISSN: 1532-7914 [Electronic] United States
• PMID: 31409173 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• BMP2 protein, human
• Bone Morphogenetic Protein 2
• Core Binding Factor Alpha 1 Subunit
• RUNX2 protein, human
• Docosahexaenoic Acids

Topics

• Bone Morphogenetic Protein 2 (antagonists & inhibitors, metabolism)
• Breast Neoplasms (drug therapy, metabolism, pathology)
• Calcinosis (drug therapy, metabolism, pathology)
• Cell Differentiation (drug effects)
• Cell Line, Tumor
• Core Binding Factor Alpha 1 Subunit (metabolism)
• Docosahexaenoic Acids (pharmacology)
• Female
• Humans
• Osteoblasts (drug effects, metabolism, pathology)
• Signal Transduction